PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Doxazosin - Benign prostatic hyperplasia
PAD Profile : Doxazosin - Benign prostatic hyperplasia
Keywords :
BPH, LUTS, urinary tract symptoms, urinary frequency, urinary incontinence
Brand Names Include :
Cardura, Doxadura
Traffic Light Status
Status 1 of 2.
Status :
Green
Preferred
Formulations :
- Immediate release tablets
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Comments :
No comments returned.
Documents :
Status 2 of 2.
Status :
Non Formulary
Important
Formulations :
- Modified release tablets
Important Information :
Use immediate release tablets
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Comments :
Do not initiate in new patients.
Review in current patients. If doxazosin remains the best option, switch to immediate release tablets in line with NHS England guidance.
Documents :
Type
Document
Review Date
Patient resource
01 January 2021
Guidelines
No guidelines returned.
Other Drugs
- Tadalafil
- Tamsulosin and dutasteride hydrochloride
- Alfuzosin hydrochloride
- Tamsulosin hydrochloride
- Terazosin hydrochloride
- Indoramin
- Prazosin hydrochloride
- Sildenafil (Erectile Dysfunction)
- Avanafil
- Vardenafil
- Solifenacin/tamsulosin
Other Indications
Additional Documents
No additional documents returned.
Committee Recommendations
Date
Committee Name
Narrative
06 December 2017
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
Where an alpha blocker is indicated, the PCN recommend one of the following as a 1st-line treatment option
- Tamsulosin (modified release) – GREEN (NOTE - prescribe as generic capsules)
- Doxazosin (immediate release) – GREEN (NOTE - XL / modified release preparations are considered BLACK)
Alfuzosin is more costly and is therefore not recommended as a 1st-line option.
Terazosin is reserved for patients with hepatic or renal failure since no dose adjustment is required in these patient groups
Associated BNF Codes
07. Obstetrics, Gynaecology and Urinary-Tract Disorders
07.04.01. Drugs for urinary retention